• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Ticagrelor and clopidogrel have similar major bleeding rates following thrombolytic therapy

byJames EnglandandAnees Daud
March 19, 2018
in Cardiology, Emergency, Imaging and Intervention, Neurology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Use of ticagrelor resulted in similar rates of major bleeding compared to clopidogrel in patients with ST elevation myocardial infarction treated with thrombolysis.

Evidence Rating Level: 2 (Good)

Study Rundown: Antiplatelet therapy is a major component of management of acute myocardial infarction. Ticagrelor results in greater and more rapid P2Y12 inhibition than clopidogrel and is shown to have a reduction in mortality from vascular events following percutaneous coronary intervention (PCI). Patients treated with fibrinolytic therapy have not been directly studied with ticagrelor because of concern for an increase in bleeding risk. This study was an open label randomized controlled trial of ticagrelor or clopidogrel for antiplatelet therapy following pharmacologic thrombolysis. The study found that at thirty days, ticagrelor was non-inferior to clopidogrel with respect to major bleeding. Minor and minimal bleeding were more common in the ticagrelor group.

The major limitation of the study was the use of clopidogrel up front prior to randomization, not allowing any conclusions to be drawn about the safety of ticagrelor first line for myocardial infarction in centers where PCI cannot be performed first line. In addition, the trial only included patients younger than 75 years, a population at lower risk for major bleeding events.

Click to read the study, published in JAMA Cardiology

Relevant Reading: Ticagrelor versus clopidogrel is associated with better recovery of LV function after Acute Myocardial Infarction

In-Depth [randomized controlled trial]: This study was a multicenter, open label, randomized controlled trial that enrolled patients with acute ST-elevation myocardial infarction under the age of 75 years, who received fibrinolytic therapy. Patients were excluded if there was a contraindication to clopidogrel, use of anticoagulation, risk of bradycardia, or use of a cytochrome P450 3A inhibitor. Patients were treated with ticagrelor (180 mg loading, then 90 mg twice daily) or clopidogrel (300-600 mg loading dose, 75 mg daily).

RELATED REPORTS

#VisualAbstract: Mobile stroke units associated with better outcomes for acute ischemic stroke management

Treatment with clopidogrel with aspirin or ticagrelor with aspirin produces similar risk reduction of stroke recurrence or death

Oral P2Y12 inhibitor pretreatment offers no benefit in non-ST elevation acute coronary syndromes

Major bleeding at 30 days, per thrombolysis in myocardial infarction (TIMI) major bleeding criteria, occurred in 0.73% of patients receiving ticagrelor and 0.69% of those receiving clopidogrel (absolute difference, 0.04%; 95%CI, −0.49% to 0.58%; p < 0.001 for noninferiority). Fatal (0.16% vs 0.11%; p = 0.67) and intracranial (0.42%vs 0.37%; p = 0.82) bleeding events were not different between the study groups. Minor bleeding occurred in 3.24% of ticagrelor patients and 2.01% of clopidogrel patients (p = 0.02).

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: clopidogrelthrombolysisTicagrelor
Previous Post

Administrative costs, provider salaries, and pharmaceutical prices drive higher healthcare spending in the United States

Next Post

Hemodynamic markers of pulmonary hypertension in heart failure with preserved ejection fraction are associated with mortality

RelatedReports

#VisualAbstract: Mobile stroke units associated with better outcomes for acute ischemic stroke management
StudyGraphics

#VisualAbstract: Mobile stroke units associated with better outcomes for acute ischemic stroke management

February 17, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Emergency

Treatment with clopidogrel with aspirin or ticagrelor with aspirin produces similar risk reduction of stroke recurrence or death

December 9, 2021
Propofol appears safe and effective in procedural sedation for cardioversion
Cardiology

Oral P2Y12 inhibitor pretreatment offers no benefit in non-ST elevation acute coronary syndromes

May 13, 2022
Colchicine may lower the risk of cardiovascular events in patients with coronary disease
Cardiology

De-escalation with clopidogrel may reduce bleeding events in patients with recent percutaneous coronary intervention

October 19, 2021
Next Post
Long-term outcomes for off-pump and on-pump CABG are similar

Hemodynamic markers of pulmonary hypertension in heart failure with preserved ejection fraction are associated with mortality

Engineered stem cells mitigate liver damage caused by radiation [PreClinical]

Human neural stem cell grafts in rhesus monkeys improve motor function after spinal cord injury [PreClinical]

Microcephaly rates elevated in Brazil prior to Zika virus epidemic

Early intrauterine Zika infection linked to birth defects among infants in the US French Territories

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.